Cimzia® (Certolizumab Pegol) is manufactured by UCB Inc. for the treatment of autoimmune diseases such as crohn’s disease (CD), moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Cimzia® is known to lower the immune system in patients taking the medication; therefore, increases the risk of serious bacterial infections (legionella and listeria), mycobacterium (tuberculosis); fungal (histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, blastomycosis, pneumocystis); and viral infections (hepatitis B).
Legionella is a very serious bacterial infection which causes a weaker disease called “Pontiac Fever.” Listeriosis is linked to other dangerous infections such as meningitis, bacteremia, endophthalmitis, and sepsis. These infections often led to life altering consequences and even death. The symptoms associated with the use of Cimzia® and its side effect infections include: fever; chills; muscle pain; headache; migraine; pneumonia; fatigue; vomiting; diarrhea; lack of concentration; impaired vision; low heart rate; and renal, liver and electrolyte disorders.